Septerna (NASDAQ:SEPN) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Septerna (NASDAQ:SEPN) issued its quarterly earnings data on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.14, FiscalAI reports. The company had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.

Septerna Stock Up 0.1%

Septerna stock opened at $38.85 on Tuesday. The firm has a market capitalization of $1.75 billion, a PE ratio of -47.96 and a beta of 2.29. The firm’s 50-day simple moving average is $34.58 and its 200 day simple moving average is $29.10. Septerna has a 52 week low of $10.62 and a 52 week high of $40.65.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Guggenheim reissued a “buy” rating and set a $51.00 price objective on shares of Septerna in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Septerna in a report on Wednesday, July 1st. Truist Financial increased their price objective on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Stifel Nicolaus initiated coverage on Septerna in a research note on Friday, May 1st. They set a “buy” rating and a $43.00 price target for the company. Finally, Raymond James Financial raised their target price on shares of Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research note on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Septerna currently has an average rating of “Moderate Buy” and an average target price of $46.56.

Insider Activity at Septerna

In related news, insider Samira Shaikhly sold 11,798 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total value of $354,647.88. Following the sale, the insider owned 793 shares of the company’s stock, valued at approximately $23,837.58. This represents a 93.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Daniel D. Long sold 15,000 shares of the stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $35.51, for a total value of $532,650.00. Following the sale, the senior vice president owned 96,412 shares in the company, valued at approximately $3,423,590.12. This trade represents a 13.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 47,828 shares of company stock valued at $1,584,314 over the last 90 days. Insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Septerna

A number of institutional investors have recently modified their holdings of SEPN. Group One Trading LLC raised its holdings in Septerna by 111.8% in the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after acquiring an additional 8,955 shares during the last quarter. Global Retirement Partners LLC acquired a new stake in shares of Septerna in the fourth quarter worth approximately $35,000. Russell Investments Group Ltd. purchased a new stake in Septerna in the third quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new position in Septerna during the fourth quarter worth approximately $53,000. Finally, BNP Paribas Financial Markets raised its stake in Septerna by 88.0% during the third quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock worth $78,000 after purchasing an additional 1,945 shares during the period.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.